US revenues of Indian pharmaceutical companies have slowed sharply amid a blitz of regulatory inspections and consolidation of the US purchasing chain -- but the news is not all bad: balance sheets are solid, margins are healthy and longer-term prospects look positive, says leading Indian investment rating agency ICRA.

The Trump presidency and the threat of protectionism, new generic opportunities beyond the US market, and the need for new quality benchmarks were some of the key issues discussed at the recent annual day celebrations of the Indian Drug Manufacturers’ Association.

Congressional oversight agency urges FDA to make better use of foreign offices with more effective performance measures and staffing goals; GAO notes agency’s progress towards risk-based inspections – and its plan to revisit every site at least once every five years.